When did Humira’s patent protection expire in 2023?
Humira (adalimumab) has faced multiple, overlapping patent and exclusivity timelines across different countries. The patent-expiration timing you may be referring to in 2023 is tied to the end of at least some exclusivity/patent protections that allowed biosimilar competition to expand in that year, rather than a single, universal “Humira patent expires everywhere on one date.”
Did Humira’s “main patent” actually expire in 2023?
Humira’s intellectual-property picture is complex because it includes:
- Separate patents that expire on different dates,
- Legal “exclusivity” protections that can extend beyond the life of specific patents,
- Country-by-country differences in patent term, approvals, and exclusivity rules.
So, even if some protections relevant to market exclusivity weakened or ended in 2023, other protections in some regions may have remained in force or been litigated.
What happened in 2023 that people associate with Humira “patent expiry”?
In practice, “Humira patent expiration” is often used as shorthand for the period when additional biosimilars gained the ability to launch or expand coverage, which depends on when protections ended and when regulators and courts allowed additional competition. That can create a year-based narrative (like 2023) even though the underlying legal dates differ by jurisdiction and by asset.
Which biosimilars competed with Humira around 2023?
Humira’s global biosimilar landscape depends on region and local regulatory decisions. If you tell me your country (US, UK, EU, Canada, etc.), I can narrow the answer to the specific biosimilars and the exact regulatory/patent-exclusivity milestones that mattered there.
Does the patent status differ between the US, EU, and the UK?
Yes. Patent term and exclusivity rules vary by jurisdiction. The end of patent protection and the end of market exclusivity are not always the same event, and they can occur in different years. That’s why searches phrased as “Humira patent expiration 2023” often yield different answers depending on where the viewer is located.
What date should you use for 2023 if you’re checking coverage or formulary impact?
For a practical “what matters on the ground” check (insurance formularies, pharmacy copays, switching timelines), the relevant date is usually when biosimilar availability increased in your country and payer system, not a single generic “patent expiration” day.
Quick question to get you the exact 2023 date
Which country are you asking about (US, EU, UK, or another)? If you share that, I can pin down the specific 2023 protections and what they enabled.
Sources
No sources were provided with your question, so I can’t cite the specific 2023 patent/exclusivity dates for Humira.